



GP-1624

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 01-1693-M)

In re Application of:

Beck et al.

Serial No.: 09/895,843

Filed: June 29, 2001

For: COMPOUNDS TO TREAT  
ALZHEIMER'S DISEASE

Group Art Unit: 1624

Examiner: Sudhaker Patel

RECEIVED

DEC 18 2002

**TRANSMITTAL LETTER**

Commissioner for Patents  
Washington, D.C. 20231


TECH CENTER 1600/2900

In regard to the above-identified patent application:

1. We are transmitting herewith the attached:
  - a) Transmittal Letter in Duplicate;
  - b) Supplemental Information Disclosure Statement
  - c) PTO Form 1449; and
  - d) Six Cited References.
2. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayments to the Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
3. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service, with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on December 13, 2002.

Respectfully submitted,

Dated: December 13, 2002

  
Steven J. Sarussi  
Reg. No. 32,784



5. Kick E.K. et al., Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D, Chemistry and Biology, April 1997, 4:297-307 U.S. Patent No. 5,583,238 issued December 10, 1996
6. Ng J.S. et al., A practical synthesis of an HIV protease inhibitor intermediate – Diastereoselective epoxide formation from chiral  $\alpha$ -aminoaldehydes, Tetrahedron Vol 51, No 23, pages 6397-6410, 1995

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff**

300 South Wacker Drive, Suite 3200

Chicago, Illinois 60606

Telephone: (312) 913-0001

Facsimile: (312) 913-0002

Dated: December 13, 2002



---

Steven J. Sarussi

Reg. No. 32,784